Gilead Provides Update on Phase 3 EVOKE-01 Study
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in…#gileadsciencesinc #phase3 #nsclc #gilead #trodelvy #merdadparsey #phd #gileadsciences #phase2 #worldconference (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2024 Category: Consumer Health News Source Type: news
Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test
Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled. The post Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test appeared first on Investor's Business Daily.#gilead #trodelvy #gild #gileadsciencesstock (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2024 Category: Consumer Health News Source Type: news
Why Is HIV Drug Giant Gilead Stock Trading Lower Today?
Gilead Sciences Inc GILD said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or…#nsclc #trop2 #gild (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2024 Category: Consumer Health News Source Type: news
Gilead ’s stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints
Shares of Gilead Sciences Inc. GILD, tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lung cancer treatment. That selloff would put the stock in danger of the biggest one-day decline since it…#gileadsciencesinc #gild #nsclc #gilead #trodelvy #merdadparsey (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2024 Category: Consumer Health News Source Type: news
Gilead's Trodelvy Fails to Meet Main Goal in Lung Cancer Trial Gilead's Trodelvy Fails to Meet Main Goal in Lung Cancer Trial
Gilead Sciences said on Monday its drug, Trodelvy, failed to significantly improve survival for previously treated patients with advanced non-small cell lung cancer (NSCLC)...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
PET/CT improves diagnostic biopsy rates in lung cancer patients
PET/CT imaging can serve as a metabolic guide to increase the accuracy of needle biopsies in patients with suspicious lung nodules, according to a study published January 18 in the European Journal of Radiology.A team that included researchers in the U.K., Greece, and the U.S. studied whether F-18 FDG-PET/CT scans showing metabolic activity of suspicious nodules improved the accuracy of CT-guided biopsies, and the group recommended the approach based on the results.“Our study showed that the availability of PET/CT prior to the [percutaneous needle lung biopsy] improves the diagnostic biopsy rates,” wrote lead author K...
Source: AuntMinnie.com Headlines - January 22, 2024 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
Kontos tapped to lead integrated diagnostics at Columbia
Despina Kontos, PhD, professor of radiology and a computer scientist with expertise in multimodality imaging data, will lead the new Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID) at Columbia University in New York.Kontos' work has contributed to a transition in the interpretation of breast cancer images by showing that imaging data can be mined to extract sophisticated phenotypic signatures with independent diagnostic, prognostic, and predictive value, according to a Columbia University Irving Medical Center statement. CIMBID will be dedicated to developing and integrating quantitative ima...
Source: AuntMinnie.com Headlines - January 19, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Position statement on lung cysts, cystic lung disease
The U.K. Cystic Lung Disease Rare Disease Collaborative Network issued a position statement in January about cystic lung disease diagnosis.Simon Johnson, PhD, professor of respiratory medicine at the University of Nottingham, and colleagues highlighted that "in many cases a multidisciplinary diagnosis can be made without the need for lung biopsy" but that in some instances tissue sampling may be necessary when noninvasive methods leave diagnostic doubt. The position statement was prompted by rare cystic lung diseases increasingly recognized as a result of wider application of CT scanning. Johnson and colleagues acknowledge...
Source: AuntMinnie.com Headlines - January 19, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Clinical News Source Type: news
How a Simple Urine Test Could Reveal Early-Stage Lung Cancer How a Simple Urine Test Could Reveal Early-Stage Lung Cancer
MIT researchers have developed nanosensors you inhale that produce a signal that can be detected in urine.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 19, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
ACS: Cancer mortality declines, but incidence rates rise
Overall cancer mortality continues to decline, but incidence rates are up, according to a January 17 report by the American Cancer Society (ACS).
The report shows that there have been more than four million fewer deaths from cancer in the U.S. since 1991. However, it also showed increased incidence for six of the top 10 cancers as the projected number of new diagnoses is over two million for the first time.
“I think we’re all grappling with what the environmental factor that is changing the cancer incidence and mortality among the young," said ACS chief scientific officer William Dahut, MD, at a press conference.
AC...
Source: AuntMinnie.com Headlines - January 17, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties CT Breast Imaging Source Type: news
Chemoradiation With SABR Boost Safe, Effective for Advanced Lung Cancer
TUESDAY, Jan. 16, 2024 -- Chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost is safe and effective for patients with locally advanced, unresectable non–small cell lung cancer (NSCLC), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 16, 2024 Category: Pharmaceuticals Source Type: news
How Obamacare Boosted Lung Cancer Survival
TUESDAY, Jan. 16, 2024 -- As more Americans with lung cancer gained access to quality care after passage of the Affordable Care Act (ACA), their post-surgical survival rates rose, new data shows.
The ACA (often called Obamacare) triggered the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 16, 2024 Category: General Medicine Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news
A Surgeon General Report Once Cleared the Air About Smoking. Is It Time for One on Vaping?
NEW YORK — Sixty years ago, the U.S. surgeon general released a report that settled a longstanding public debate about the dangers of cigarettes and led to huge changes in smoking in America.
Today, some public health experts say a similar report could help clear the air about vaping.
[time-brightcove not-tgx=”true”]
Many U.S. adults believe nicotine vaping is as harmful as — or more dangerous than — cigarette smoking. That’s wrong. The U.S. Food and Drug Administration and most scientists agree that, based on available evidence, electronic cigarettes are far less danger...
Source: TIME: Health - January 15, 2024 Category: Consumer Health News Authors: Mike Stobbe / AP Tags: Uncategorized wire Source Type: news
